Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis
about
Bone and TNF in rheumatoid arthritis: clinical implicationsEffects of anti-tumor necrosis factor α agents on boneBiochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placeboBiologic therapies and bone loss in rheumatoid arthritis.Bone remodelling markers in rheumatoid arthritis.Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 monthsInitiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseasesBone effects of biologic drugs in rheumatoid arthritis.Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized studyT-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritisInfliximab in the treatment of rheumatoid arthritisPrevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy.Application of biochemical markers in development of drugs for treatment of osteoarthritis.Could biomarkers of bone, cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients?Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab.Osteoporosis in inflammatory joint diseases.Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.Therapeutic targeting of osteoclast function and pathways.Pharmacodynamics of bisphosphonates in arthritis.Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.Management of osteoporosis in rheumatoid arthritis patients.The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.Physiological and pathophysiological bone turnover - role of the immune system.Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease.Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice.Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study.Decrease of Markers Related to Bone Erosion in Serum of Patients with Musculoskeletal Disorders after Serial Low-Dose Radon Spa Therapy.Role of glucocorticoid-induced leucine zipper (GILZ) in inflammatory bone loss.Adalimumab for refractory peripheral ulcerative keratitis.Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis.Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation.Celecoxib, a selective cyclooxygenase-2 inhibitor, reduces level of a bone resorption marker in postmenopausal women with rheumatoid arthritis.Paradoxical elevation of serum TRACP5b levels despite increase in lumbar spine bone mineral density during anti-TNFα therapy in patients with inflammatory rheumatic disease: a 2-year prospective assessment of bone mass, bone metabolism, and the trabBiologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over.Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis.
P2860
Q26777895-EDC36A70-DE86-48E6-80AF-4D252082A7EEQ26851274-C6BEC8D6-E14D-4E66-BD1A-DB901E93FCCEQ27687777-1DC9C5CD-F35A-4E39-BC37-61ACE6F1246AQ28475485-7BA1CBBD-19C3-43DF-AEC8-9CA9D8C399A1Q30243911-D1E31B24-3C5E-4775-8F19-FEFD4103D737Q33563068-CFD40E73-2159-4574-81C6-BBA3C3C0CB0DQ34346418-A4C25371-69D5-4C61-821B-8DEE142B09D8Q36781280-F6359143-38ED-4BE6-AE68-3A38514E416CQ36995387-86B0D1E6-643A-4937-8F81-C5EE5EDC3385Q37051820-6097E23F-44CB-41A4-963C-7D6424AF6959Q37129537-ED8FF726-225F-42ED-981A-4CDBF7EE2AA3Q37129568-540E87AD-03D1-4DF5-8697-D005DBB1B0A5Q37303230-41FCC11D-6311-4879-A5AC-4E419DA025A1Q37307876-088DD15B-87C2-4C3A-8B9E-BCF8A74BCDEFQ37677789-A966A221-9CDF-484B-90F6-4FC01B3E3778Q37679653-8C2D8923-9F1A-4839-A372-40E1AEE50106Q37703466-5CD32876-0499-45FC-9C3C-193F02090636Q37765505-E547DBDA-F55B-41C6-9AFB-19385160DB46Q37801555-4AFF535F-BE7A-4D02-9E27-9852635CD736Q37825905-144B980F-A4F1-451D-BD35-E7F3A5A39FF3Q37973356-400142DC-F113-4232-96ED-33BDD71AA00AQ38041419-440925CB-E974-419D-88D1-EF6C77C4A7AAQ38334318-8622BF79-C0D0-4121-81F9-B81BD7E7F16BQ38831693-81A0B532-A3F2-48B7-81E3-4355F816B56FQ38867785-4B4A4796-AB57-415F-85FF-7239C71BD632Q39035413-ED824054-062F-42D8-8000-5A8599FE9E31Q39085876-6E0A2EA6-2300-4E87-95F5-E15DDD5D00E4Q40079134-B3FEB63B-2C4B-45C8-9038-DDD3588C9487Q41108607-2F1392BA-6C2D-4804-A77C-FF418436E137Q41236945-D8588F79-C166-4FDF-AC0E-31179A43B900Q41457317-5DED89EC-9A81-434E-8816-EAB63DDBCDDDQ41883420-870DBBFA-0E49-4773-B3EC-2D4130334886Q42045687-6DC68DFE-D3CF-4D4F-9FD5-91936E2231EDQ43971550-01A16819-D60B-4AFF-83C8-6691DD22F124Q45832844-6F419C57-5F91-4660-A5E3-C54395AE0067Q46155482-26A05A80-A07F-4168-AAF4-661395E9EA0EQ54014686-8EA4653E-7D60-4D7F-8F8A-EBBCDE206839
P2860
Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis
description
im Oktober 2007 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2007
@uk
name
Long-term effects of inflixima ...... ents with rheumatoid arthritis
@en
Long-term effects of inflixima ...... ents with rheumatoid arthritis
@nl
type
label
Long-term effects of inflixima ...... ents with rheumatoid arthritis
@en
Long-term effects of inflixima ...... ents with rheumatoid arthritis
@nl
prefLabel
Long-term effects of inflixima ...... ents with rheumatoid arthritis
@en
Long-term effects of inflixima ...... ents with rheumatoid arthritis
@nl
P2093
P356
P1476
Long-term effects of inflixima ...... ents with rheumatoid arthritis
@en
P2093
A le Henanff
C Zarnitsky
D Wendling
P304
P356
10.1136/ARD.2007.076604
P407
P577
2007-10-29T00:00:00Z